Alto Neuroscience, Inc. (ANRO)
| Market Cap | 922.97M+296.0% |
| Revenue (ttm) | n/a |
| Net Income | -84.24M |
| EPS | -2.31 |
| Shares Out | 39.24M |
| PE Ratio | n/a |
| Forward PE | -7.16 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 346,246 |
| Open | 23.39 |
| Previous Close | 23.69 |
| Day's Range | 23.32 - 24.40 |
| 52-Week Range | 5.22 - 37.48 |
| Beta | 1.34 |
| Analysts | Strong Buy |
| Price Target | 38.38(+63.19%) |
| Earnings Date | Nov 11, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About ANRO
Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ANRO stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in ANRO holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ANRO's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ANRO Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New ANRO patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ANRO from public contracts
Source: USAspending.gov
ANRO Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ANRO’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score